Berberine (BBR) is the main active ingredient of the ancient Chinese herb medicine Coptis. The hypoglycemic effect of BBR has been demonstrated in numerous studies. Although BBR is safe and effective in the treatment of diabetes, its exact hypoglycemic mechanism is still unclear. Jin-Kui Yang found that BBR can promote GLP-1 secretion from intestinal L cells in mice in vitro and in vivo, thereby achieving the effect of lowering blood glucose, but it is still unknown whether BBR can promote incretin secretion in humans. In this study, investigators plan to examine the effect of BBR on secretion of incretin in human.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
16
Traditional Chinese medicine
Placebo control
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Hao Wang
Beijing, China
Differences of serum GLP-1 levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean serum GLP-1 in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of serum GIP levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean serum GIP levels in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of blood glucose levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean blood glucose levels in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of serum insulin levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean insulin levels in the two groups during glucose tolerance test.
Time frame: The time frame is the same as Primary Outcome Measure 1
Differences of serum C-peptide levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean serum C-peptide levels in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of serum potassium levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean serum potassium levels in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of serum sodium levels between BBR and placebo treatment groups during the glucose tolerance test.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To compare the mean serum sodium levels in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of serum chloride levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean serum chloride levels in the two groups during glucose tolerance test.
Time frame: 4 hours
Differences of serum calcium levels between BBR and placebo treatment groups during the glucose tolerance test.
To compare the mean serum calcium levels in the two groups during glucose tolerance test.
Time frame: 4 hours